<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00008190</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068386</org_study_id>
    <secondary_id>CPMC-IRB-8872</secondary_id>
    <secondary_id>CPMC-CAMP-27</secondary_id>
    <secondary_id>NCI-G00-1889</secondary_id>
    <nct_id>NCT00008190</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Acute Leukemia</brief_title>
  <official_title>High Dose Chemotherapy And Autologous Peripheral Blood Stem Cell Rescue For High Risk Acute Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herbert Irving Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation&#xD;
      may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells.&#xD;
      Interleukin-2 may stimulate a person's white blood cells to kill leukemia cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by&#xD;
      peripheral stem cell transplantation and interleukin-2 in treating patients who have acute&#xD;
      leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the efficacy of busulfan, cyclophosphamide, and etoposide followed by&#xD;
           autologous peripheral blood stem cell transplantation and interleukin-2 in patients with&#xD;
           high-risk acute leukemia.&#xD;
&#xD;
        -  Determine the efficacy of immunomodulatory therapies in terms of relapse-free survival&#xD;
           of these patients treated with this regimen.&#xD;
&#xD;
        -  Determine the hematopoietic reconstitution, relapse, and survival of these patients&#xD;
           treated with this regimen.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: Following a course of mobilization chemotherapy, patients receive priming therapy&#xD;
      comprising filgrastim (G-CSF) and interleukin-2 through the completion of leukapheresis.&#xD;
      Patients then receive oral busulfan 4 times daily on days -8 through -5, cyclophosphamide IV&#xD;
      continuously on days -4 and -3, and etoposide IV over 2 hours on day -4. For patients unable&#xD;
      to receive cyclophosphamide and etoposide, melphalan IV is administered instead on days -3&#xD;
      and -2. Autologous peripheral blood stem cells (PBSC) are reinfused on day 0.&#xD;
&#xD;
      Patients then receive G-CSF daily beginning on day 0 and continuing until blood counts&#xD;
      recover followed by interleukin-2 subcutaneously daily beginning at the completion of G-CSF&#xD;
      therapy and continuing for 6 months.&#xD;
&#xD;
      Patients are followed weekly for 1 month and then monthly thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 19-25 patients will be accrued for this study within 3-5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1999</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed acute leukemia&#xD;
&#xD;
               -  High-risk due to any of the following:&#xD;
&#xD;
                    -  Cytogenetic abnormalities involving 5q, 7q, 8q, 11q23, or t(9;22)&#xD;
&#xD;
                    -  WBC greater than 100,000/mm3&#xD;
&#xD;
                    -  Prior myelodysplastic syndrome&#xD;
&#xD;
                    -  Complete remission (CR) lasting less than 12 months&#xD;
&#xD;
               -  No favorable cytogenetic parameters (e.g., t(15;17), inv16, or t(8;21))&#xD;
&#xD;
          -  CR following standard anti-leukemic therapy confirmed by bone marrow evaluation&#xD;
&#xD;
               -  Second and third CR allowed&#xD;
&#xD;
          -  Ineligible for higher priority national or institutional study or allogeneic&#xD;
             peripheral blood stem cell transplantation&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Any age&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 1.5 times normal&#xD;
&#xD;
          -  SGOT or SGPT less than 1.5 times normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 1.5 times normal&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  LVEF at least 45% if receiving cyclophosphamide&#xD;
&#xD;
          -  Normal electrocardiogram OR&#xD;
&#xD;
          -  Approval by cardiologist&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  DLCO less than 60% predicted OR&#xD;
&#xD;
          -  Approval by pulmonologist&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  No concurrent illness that would preclude study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles S. Hesdorffer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Herbert Irving Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center at Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2004</verification_date>
  <study_first_submitted>January 6, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>February 1, 2013</last_update_submitted>
  <last_update_submitted_qc>February 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2013</last_update_posted>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

